Author

Bo Shui

Cornell UniversityPrimary ORCID profile (0000-0001-5744-9886 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Bo ShuiiD1 paper · Cornell University

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Assay:scRNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

Andreas StephanouiD· 1 shared Deanna MischeiD· 1 shared Gerald E. DuhameliD· 1 shared Iwijn De VlaminckiD· 1 shared Jennifer K. GrenieriD· 1 shared Marina ChaniD· 1 shared Michael J. ByroniD· 1 shared Praveen SethupathyiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andreas StephanouORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Neuroepithelial reprogramming and ERBB vulnerability in canine acanthomatous ameloblastoma

Andreas Stephanou, Bo Shui, Deanna Mische, Michael J. Byron, William P. Katt, Marina Chan, Jennifer K. Grenier, Iwijn De Vlaminck, Gerald E. Duhamel, Taranjit S. Gujral, Praveen Sethupathy, Santiago Peralta

This study uses single-nucleus RNA-seq to identify unique neuroepithelial features in canine acanthomatous ameloblastoma, revealing ERBB4 as a therapeutic target.

Molecular Therapy Oncology · Jul 22, 2026Peer-reviewedCancer Biology